The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial

Autor: Jacqueline A E Langius, M.A.E. de van der Schueren, A.J. ten Tije, Annelie Vulink, A. Haringhuizen, H.J. van der Vliet, Aart Beeker, Johannes Berkhof, Henk M.W. Verheul, A. van der Werf
Přispěvatelé: Internal medicine, Medical oncology, CCA - Cancer Treatment and quality of life, Epidemiology and Data Science, APH - Methodology, Amsterdam Gastroenterology Endocrinology Metabolism, APH - Health Behaviors & Chronic Diseases, APH - Aging & Later Life
Rok vydání: 2020
Předmět:
0301 basic medicine
Counseling
Male
medicine.medical_specialty
Sarcopenia
Time Factors
Colorectal cancer
medicine.medical_treatment
030209 endocrinology & metabolism
Antineoplastic Agents
Critical Care and Intensive Care Medicine
Weight Gain
Enteral administration
law.invention
03 medical and health sciences
Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
medicine
Humans
Single-Blind Method
Progression-free survival
Neoplasm Metastasis
Muscle
Skeletal
Aged
Netherlands
Chemotherapy
030109 nutrition & dietetics
Nutrition and Dietetics
business.industry
Nutritional Support
Cancer
Middle Aged
medicine.disease
Progression-Free Survival
Clinical trial
Body Composition
Female
business
Colorectal Neoplasms
Tomography
X-Ray Computed
Zdroj: Clinical Nutrition Supplements, 39, 10, pp. 3005-3013
van der Werf, A, Langius, J A E, Beeker, A, Ten Tije, A J, Vulink, A J, Haringhuizen, A, Berkhof, J, van der Vliet, H J, Verheul, H M W & de van der Schueren, M A E 2020, ' The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy : A randomized controlled trial ', Clinical Nutrition, vol. 39, no. 10, pp. 3005-3013 . https://doi.org/10.1016/j.clnu.2020.01.009
Clinical Nutrition Supplements, 39, 3005-3013
Clinical Nutrition, 39(10), 3005-3013. Churchill Livingstone
Clinical Nutrition, 39, 3005-3013
ISSN: 3005-3013
1744-1161
0261-5614
DOI: 10.1016/j.clnu.2020.01.009
Popis: Contains fulltext : 229520.pdf (Publisher’s version ) (Closed access) BACKGROUND & AIMS: A low muscle mass before start of treatment and loss of muscle mass during chemotherapy is related to adverse outcomes in patients with cancer. In this randomized controlled trial, the effect of nutritional counseling on change in muscle mass and treatment outcome in patients with metastatic colorectal cancer during first-line chemotherapy was studied. METHODS: Patients scheduled for first-line chemotherapy (n = 107) were randomly assigned to individualized nutritional counseling by a dietitian (NC) or usual care (UC). NC was aimed at sufficient protein- and energy intake, supported by oral supplements or enteral feeding if indicated. Furthermore, physical activity was encouraged. Outcomes were assessed at baseline (T0) and the time of the first (T1) and second (T2) regular follow-up computed tomography scans. The proportion of patients with a clinically relevant decrease in skeletal muscle area of ≥6.0 cm(2), measured by computed tomography, was the primary outcome. Secondary outcomes included body weight, quality of life, treatment toxicity and progression free and overall survival. RESULTS: A total of 107 patients were enrolled (mean age, 65 years (SD, 11 years), 63% male). Mean change in skeletal muscle area from T0 till T1 was -2.5 (SD, 9.5) cm(2), with no difference between NC versus UC (p = 0.891). The proportion of patients with a clinically relevant decrease in skeletal muscle area of ≥6.0 cm(2) did not differ (NC 30% versus UC 31%, p = 0.467). NC compared with UC had a significant positive effect on body weight (B coefficient 1.7, p = 0.045), progression free survival (p = 0.039) and overall survival (p = 0.046). CONCLUSIONS: NC of patients undergoing chemotherapy for metastatic colorectal cancer had no effect on muscle mass. However, we found that NC may increase body weight and improve progression free survival and overall survival compared to UC in this group of patients. These findings need further evaluation in future clinical trials. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov NCT01998152; Netherlands Trial Register NTR4223.
Databáze: OpenAIRE
Externí odkaz: